Fungal meningitis outbreak in the US
Fungal meningitis is rare and usually the result of spread of a fungus through blood to the spinal cord. Although anyone can get fungal meningitis, people with weak immune systems, like those with AIDS or cancer, are at higher risk.
There are lots of ways fungus could have gotten inside the Mass. compounding pharmacy whose steroid medication has been linked to a lethal outbreak of a rare fungal form of meningitis.
A report issued by Republicans states that the FDA failed to act on years of complaints about problematic drugs and practices at the New England Compounding Center.
The troubled Department of Public Health would receive an additional $3.1 million in state funding to hire more inspectors to monitor compounding pharmacies and to increase other public safety efforts, under Governor Deval Patricks proposed budget.
Bankruptcy records show that the owners of the Mass. pharmacy linked to a nationwide fungal meningitis outbreak that has killed dozens of people pulled millions of dollars out of the company in the last year.
Governor Deval Patrick announced plans to reorganize the board of pharmacy to add professionals from other fields, give the board the authority to regulate out-of-state compounders that distribute in Mass.
A Westborough drug company with the same owners as the Framingham specialty pharmacy at the center of the national fungal meningitis outbreak will remain closed until at least February 22, public health regulators said Thursday.
Meningitis sickened hundreds in late summer and early fall, but a frightening second wave of fungal infections was caused by contaminated drugs. Dozens more people have now been diagnosed with excruciating abscesses or inflamed nerves in their backs that are proving formidable to cure.
Under the new rules, specialty pharmacies similar to the Framingham company whose contaminated drugs are blamed for the outbreak, are required to report to state regulators the volume of medications they are making and whether they have detected contamination in their laboratories.
The state's public defender agency may need up to $332 million to represent thousands prosecuted with evidence potentially tainted at a now-closed state drug lab. (Globe)
The head of the FDA asked Congress for more authority to police pharmacies like the one that triggered a deadly meningitis outbreak, even as lawmakers questioned why the agency didnt do more with its existing powers.
Barry Cadden, co-owner of the Framingham compounding pharmacy linked to a national meningitis outbreak, refused to answer questions yesterday at a congressional hearing.
State pharmacy regulators on at least two occasions in the past decade displayed indifference in their oversight of a troubled Framingham specialty pharmacy that has now been blamed for a national fungal meningitis outbreak, according to documents obtained by the Globe Tuesday. (Boston Globe)
Years before meningitis outbreak, Barry Cadden was uncooperative with the FDA, congressional staff says.
The director of the state pharmacy board, James D. Coffey, has been fired for allegedly ignoring a complaint in July that New England Compounding Center was distributing bulk shipments of drugs to hospitals in Colorado, in violation of its state licenses.
Congressional investigators Tuesday subpoenaed Barry Cadden, co-owner of the Framingham pharmacy blamed for the national meningitis outbreak, to answer questions about the crisis in Washington next week.
Massachusetts regulators have ordered those who worked at the Framingham company to immediately stop working in the drug-compounding industry.
The Patrick administration Thursday unveiled new emergency regulations to more tightly oversee compounding pharamacies like the Framingham facility linked to the national fungal meningitis outbreak.
Ameridose LLC, sister company to the Framingham pharmacy whose drugs have been implicated in hundreds of fungal infections and 29 deaths, issued a recall of all its products Wednesday.
Shortly before a national fungal meningitis outbreak was linked to NECC, the Framingham company sent customers a Quality Assurance Report Card trumpeting the cleanliness of its labs, even as internal tests showed widespread contamination.
BE WELL, BOSTON | VIDEO
What do you really need to know about the fungal meningitis outbreak? Are you at risk?
The pharmacy is similar to the Framingham compounding center tied to a national fungal meningitis outbreak, officials said.
The US FDA found visible mold inside the Framingham pharmacy at the center of the national fungal meningitis outbreak.
New England Compounding Center lawyers say action would stem flow of lawsuits.
A Westborough pharmacy with the same owners as the Framingham specialty phamacy at the center of the nationwide fungal meningitis outbreak will remain closed until at least Nov. 5.
Separate lawsuits seeking a total of $15 million have been filed in Virginia against a Massachusetts pharmacy that is at the center of an outbreak of rare fungal meningitis.
Fungal meningitis is usually exceedingly difficult to diagnose, and the treatment is risky and arduous.
Federal health officials said today that people should be warned who got any injectable drugs -- not just steroid injections -- made by a Framingham facility at the center of a meningitis outbreak.
New Hampshire Attorney General Michael Delaney said that New England Compounding Center agreed to surrender its privileges to sell mail-order pharmaceuticals in the Granite State.
Federal regulators said they have confirmed the presence of a fungus in unopened vials of steroids from the troubled Framingham pharmacy at the center of a nationwide meningitis outbreak that matches the type of infection found in most of the sick patients.
State and federal health officials have identified a Framingham pharmacy as the source of injectable steroids that may have infected people with a rare form of fungal meningitis.